Choksi Laboratories Schedules Board Meeting on May 25, 2026 to Approve Q4 and Full-Year FY26 Audited Results
Choksi Laboratories has scheduled its 02/2026-27 Board of Directors meeting for May 25, 2026, at 02:30 P.M. at its registered office in Indore, to consider and approve standalone audited financial results for Q4 and the year ended March 31, 2026. The intimation was filed pursuant to Regulation 29(1) of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015. The trading window, closed since April 1, 2026, will reopen 48 hours after the declaration of the audited results. The filing was submitted by Company Secretary and Compliance Officer Prakhar Dubey on May 16, 2026.

*this image is generated using AI for illustrative purposes only.
Choksi Laboratories has notified BSE Limited of its forthcoming Board of Directors meeting, filed in compliance with Regulation 29(1) of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015. The meeting, designated as the 02/2026-27 board meeting, has been scheduled for Monday, May 25, 2026, at 02:30 P.M., to be held at the company's registered office located at Survey No. 9/1, Near Tulsiyana Industrial Park, Kumerdi, Indore, 453555 (M.P.).
Board Meeting Agenda
The board meeting has been convened to deliberate on key financial and administrative matters. The following items are on the agenda:
| Agenda Item: | Details |
|---|---|
| Primary Business: | Consider and approve standalone audited financial results for Q4 and year ended March 31, 2026 |
| Additional Business: | Any other item with permission of the Chairman and consent of majority of Directors present, including at least one independent Director |
The company has also confirmed that the required disclosures will be submitted in both XBRL mode (using the excel template provided by the Exchange) and PDF mode within the prescribed time limit.
Trading Window Closure
In continuation of an earlier disclosure dated March 26, 2026, Choksi Laboratories has reiterated that the trading window for dealing in the securities of the company has been closed with effect from April 1, 2026, pursuant to the SEBI (Prohibition of Insider Trading) Regulations, 2015, as amended.
The trading window will reopen 48 hours after the declaration of the audited financial results for the quarter and year ended March 31, 2026. This restriction applies to all designated persons, their immediate relatives, and all connected persons covered under the aforesaid code.
Regulatory Filing Details
The intimation was signed and submitted by Prakhar Dubey, Company Secretary and Compliance Officer, on May 16, 2026, and has been addressed to the Corporate Relationship Department of BSE Limited. The company has requested BSE to take the information on record and disseminate it on the BSE website.
Historical Stock Returns for Choksi Laboratories
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -5.62% | -0.60% | +0.66% | -29.31% | -15.42% | +903.04% |
How might Choksi Laboratories' Q4 and full-year FY2026 financial results compare to its previous year's performance, and what growth trajectory could investors expect?
Will the board meeting on May 25, 2026 include any discussions on dividend declarations or capital allocation strategies beyond the financial results approval?
How could the trading window reopening 48 hours after the results announcement impact short-term price volatility in Choksi Laboratories' stock?

































